Summary
A comparison of the adverse effects of the depot preparations of flupenthixol decanoate (Depixol®) and fluphenazine decanoate (Modecate®) was conducted in 100 chronic schizophrenic patients attending the outpatient department at the Psychiatric Hospital, Bahrain.
Although akathisia, parkinsonism, weight gain and endocrine effects were seen in a large number of cases, there was no statistically significant difference in their incidence between the 2 groups. Furthermore, there was no difference in the efficacy of the 2 preparations studied.
We observed abnormal hair loss in 42 cases — 22 on Depixol® and 20 on Modecate®. This previously unreported side effect is probably due to these long-acting antipsychotic drugs.
Similar content being viewed by others
References
Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In Gilman et al. (Eds) The Pharmacological Basis of Therapeutics, pp. 398–400, Pergammon Press, New York, 1990
Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses. Archives of General Psychiatry 45: 79–91, 1988
Choninard G, Ross-Choninard A, Annable L, et al. Extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences 7: 233–236, 1980
Hyde C. The Manchester Scale. British Journal of Psychiatry 155(Suppl. 7): 46–48, 1989
Johnson DAW, Malik NA. A double-blind comparison of flu-phenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. Acta Psychiatrica Scandinavica 51: 257–267, 1975
Kesseler KA, Waletzky JP. Survey in the maintenance therapy of chronic schizophrenic patients. American Journal of Psychiatry 2: 138, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shooka, A., Al Haddad, M.K. & Mathur, V. Adverse Effects of Two Long-Acting Depot Antipsychotic Drugs. Drug Invest. 6, 110–113 (1993). https://doi.org/10.1007/BF03258461
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258461